The global CRISPR/Cas9
licensing leader

Based on the Nobel Prize winning invention of Emmanuelle Charpentier & Jennifer Doudna, CRISPR/Cas9 has transformed gene editing. ERS licenses worldwide access to the essential CRISPR/Cas9 patent portfolio.

"This is transformative technology that allows the recoding of life and editing"

Emmanuelle Charpentier
ERS co-founder, patent co-owner
& 2020 Nobel prize winner

The essential intellectual property for the practice of CRISPR/Cas9

Consisting of over 85 issued patents in over 80 countries, our portfolio represents the most foundational collection of CRISPR/Cas9 patents worldwide.

Latest news